Last updated: September 8, 2026
Ripretinib is a targeted therapy for advanced gastrointestinal stromal tumor (GIST) marketed as Qinlock. Deciphera Pharmaceuticals developed the drug and commercialized it until Ono Pharmaceutical acquired Deciphera in 2024 for approximately $2.4 billion. Qinlock generated more than $200 million in annual product revenue before the acquisition, with growth driven by its role as the FDA-approved fourth-line treatment for advanced GIST.
The commercial outlook is positive but constrained by the size of the fourth-line market, competition from avapritinib, regorafenib and other tyrosine kinase inhibitors, and the limited number of patients who remain eligible after multiple prior therapies. U.S. patent protection extends beyond statutory regulatory exclusivity, giving Ono time to defend the franchise against generic entry. The key commercial question is whether Qinlock can expand earlier in the treatment sequence or sustain growth through international penetration and combination-treatment development.
What is ripretinib and how is Qinlock used?
Ripretinib is a switch-control tyrosine kinase inhibitor that inhibits KIT and PDGFRA signaling, including multiple mutations associated with treatment-resistant GIST. FDA approved Qinlock in May 2020 for adults with advanced GIST who previously received treatment with three or more kinase inhibitors, including imatinib.[1]
The approved treatment is 150 mg orally once daily. Patients who progress on the standard dose may receive 150 mg twice daily under the prescribing information.[1]
What disease segment does Qinlock target?
Qinlock addresses advanced or metastatic GIST after failure of:
- Imatinib.
- Sunitinib.
- Regorafenib.
This positioning gives Qinlock a differentiated place in the treatment algorithm. It also limits the addressable market because most patients either respond to earlier therapy, discontinue treatment because of toxicity, or do not remain fit enough to receive fourth-line therapy.
The pivotal INVICTUS trial showed a median progression-free survival of 6.3 months with ripretinib versus 1.0 month with placebo. Median overall survival was 15.1 months with ripretinib versus 6.6 months with placebo.[1,2]
How large is the ripretinib market?
The commercial market is concentrated in the United States, where Qinlock has the clearest reimbursement and treatment-pathway position. International sales add geographic breadth but generally have lower pricing and slower uptake.
Qinlock revenue trajectory
Deciphera reported the following Qinlock net product revenue before its acquisition by Ono:
| Fiscal year |
Qinlock net product revenue |
Approximate growth |
| 2020 |
$43 million |
Initial launch year |
| 2021 |
$130 million |
Approximately 200% |
| 2022 |
$174 million |
Approximately 34% |
| 2023 |
$211 million |
Approximately 22% |
Sources: Deciphera Pharmaceuticals annual reports and Form 10-K filings.[3,4]
Revenue growth remained positive through 2023, but the rate moderated as Qinlock matured in the U.S. fourth-line market. The trajectory reflects increased physician adoption, longer treatment duration, broader payer coverage and international launches rather than a major expansion of the labeled population.
Deciphera reported approximately $57 million of Qinlock revenue in the first quarter of 2024, indicating continued year-over-year growth before Ono completed the acquisition.[5] Ono subsequently assumed commercial responsibility for Qinlock.
What drives Qinlock sales?
The main revenue drivers are:
- Continued diagnosis and treatment of advanced GIST.
- Use after failure of imatinib, sunitinib and regorafenib.
- Persistent treatment with an oral therapy that is generally easier to administer than intravenous alternatives.
- International reimbursement and regulatory approvals.
- Physician confidence in ripretinib’s activity across heterogeneous KIT mutations.
- Limited direct competition in the fourth-line setting.
Pricing is also material. Qinlock is a specialty oncology product with a U.S. list price materially above the cost of older generic kinase inhibitors. Net sales depend on discounts, rebates, patient assistance and payer mix.
What is the financial outlook for ripretinib?
Qinlock’s revenue base is likely to continue growing, but the drug is moving from launch expansion toward franchise optimization.
Base-case trajectory
A reasonable base-case commercial trajectory is:
| Period |
Expected commercial phase |
Main factors |
| 2024-2025 |
Continued growth |
U.S. penetration, international launches, Ono integration |
| 2026-2028 |
Mature growth |
Stable fourth-line demand and geographic expansion |
| 2029 onward |
Slower growth |
Market saturation, competing therapies and patent-risk preparation |
The product’s sales ceiling is lower than that of first-line oncology therapies because the eligible population is narrow. The addressable market could expand if ripretinib demonstrates meaningful benefit in earlier lines or in molecularly defined subgroups.
What is the impact of the Ono acquisition?
Ono agreed to acquire Deciphera in April 2024 for $25.60 per share in cash, implying an equity value of approximately $2.4 billion. The transaction closed in June 2024.[6]
The acquisition gave Ono:
- Qinlock, an approved commercial product.
- Deciphera’s oncology commercial infrastructure.
- Ripretinib development rights and international operations.
- Vimseltinib, another kinase inhibitor in Deciphera’s pipeline.
- A U.S. commercial platform that complements Ono’s existing oncology portfolio.
For Qinlock, the transaction reduces standalone-company overhead and gives the product access to Ono’s international infrastructure. It also changes the financial reporting framework. Future product economics are reported within Ono rather than through Deciphera’s former quarterly revenue disclosures.
The purchase price indicates that Ono valued Qinlock as a durable specialty oncology asset rather than as a near-term high-growth product. The acquisition also reflects the strategic value of adding a marketed drug with an established physician base and patent protection extending beyond the initial regulatory exclusivity period.
What patents protect ripretinib and Qinlock?
Qinlock is protected by compound, formulation and related patent rights listed in the FDA Orange Book. The principal U.S. patents are associated with ripretinib and its pharmaceutical compositions.
U.S. patent protection
Publicly reported Qinlock patent protection includes:
| Patent category |
Commercial relevance |
| Ripretinib compound patents |
Protect the active pharmaceutical ingredient |
| Pharmaceutical-composition patents |
Protect formulations containing ripretinib |
| Treatment patents |
Protect use in advanced GIST and related treatment methods |
| Manufacturing and process rights |
May restrict practical development of alternative manufacturing routes |
The principal U.S. compound protection is expected to extend into the mid-2030s, subject to patent-term adjustment, patent-term extension and the scope of Orange Book-listed claims. FDA regulatory exclusivity is shorter than the patent term.
FDA approved Qinlock on May 15, 2020. The five-year new chemical entity exclusivity period therefore expired in May 2025. Qinlock also received orphan-drug designation for GIST, providing seven years of orphan exclusivity in the United States, generally extending through May 2027 for the approved indication.[1,7]
Patent expiry is the more important long-term issue because it may continue to delay generic approval after regulatory exclusivity ends.
Does Qinlock have formulation and method-of-use protection?
Yes. Qinlock’s intellectual-property position is not limited to the active molecule. Listed and related rights cover pharmaceutical compositions and therapeutic use.
Method-of-use protection is particularly relevant because the FDA indication specifies treatment of advanced GIST after prior kinase-inhibitor therapy. A generic applicant may attempt to avoid infringement through a section viii statement that omits patented methods, but the commercial effect depends on the remaining unprotected uses, prescribing behavior and the scope of the Orange Book listing.
Formulation patents can create a second barrier if they cover the marketed dosage form or commercially important dosage strengths. Their practical value depends on claim breadth, validity and whether a generic can develop a non-infringing formulation.
When does ripretinib lose exclusivity?
Qinlock’s regulatory exclusivity and patent exclusivity occur on different timelines.
| Exclusivity type |
Expected timing |
| FDA new chemical entity exclusivity |
Expired in May 2025 |
| Orphan-drug exclusivity for the approved GIST indication |
Generally through May 2027 |
| Core U.S. patent protection |
Expected into the mid-2030s, subject to applicable adjustments |
| Generic launch risk |
More likely after final patent expiry or an earlier settlement |
The first generic filing date does not determine launch. A Paragraph IV challenge can initiate litigation years before patent expiry. The outcome could be a judgment of validity and infringement, a settlement with a licensed launch date, or an earlier generic entry if the challenger prevails.
What is the Orange Book status of Qinlock?
Qinlock is an FDA-approved prescription drug listed in the Orange Book under ripretinib. Orange Book-listed patents provide the basis for patent certifications submitted with abbreviated new drug applications.
The commercial relevance of each listing depends on:
- The patent’s expiration date.
- Whether the patent is eligible for Orange Book listing.
- Whether a generic applicant certifies Paragraph IV.
- Whether the patent covers the active ingredient, dosage form or use.
- Whether the FDA accepts a section viii carve-out.
- Whether the patent holder files suit within the statutory period.
FDA Orange Book records should be treated as the controlling source for current patent listings and expiration dates. Ono’s commercial defense strategy will depend on maintaining enforceable listings and pursuing timely litigation where required.[7]
Which companies are challenging ripretinib patents?
Publicly available company filings through the Deciphera ownership period did not establish a broad, disclosed Paragraph IV challenge comparable to the generic challenges affecting older blockbuster kinase inhibitors. The most important future challengers are likely to be large generic manufacturers with oncology capabilities and firms that specialize in complex oral solid-dose products.
Potential challenger profiles include:
- Large U.S. generic companies.
- Indian manufacturers with oncology ANDA infrastructure.
- Companies with experience developing kinase-inhibitor formulations.
- Contract manufacturers that can produce ripretinib at scale.
The absence of a prominent public challenge does not eliminate future risk. Once the FDA exclusivity period has expired, an ANDA filing can be made with a Paragraph IV certification against remaining Orange Book patents.
What patent litigation affects Qinlock?
The main litigation risk is prospective rather than a demonstrated broad litigation campaign. A generic applicant that makes a Paragraph IV certification would likely trigger patent litigation under the Hatch-Waxman framework if Ono files suit within 45 days.
Potential litigation issues include:
- Whether the ripretinib compound claims are valid.
- Obviousness based on earlier KIT and PDGFRA inhibitors.
- Written-description and enablement challenges.
- Infringement of formulation claims.
- The scope of treatment-method claims.
- Patent-term adjustment and patent-term extension.
- Whether a generic can launch with a legally effective label carve-out.
The strength of the estate is highest where claims cover the specific active compound and commercially necessary formulation. Method-of-use patents generally provide a narrower barrier because generic labels may omit protected indications.
How strong is the ripretinib patent estate?
Ripretinib has a commercially meaningful patent estate because the product is a small-molecule oncology drug with core compound protection extending materially beyond the orphan and new chemical entity exclusivity periods.
Strengths
- A defined molecular target and differentiated switch-control mechanism.
- Core compound protection expected to extend into the 2030s.
- FDA-approved indication with a clear treatment sequence.
- Potential formulation and use claims.
- A high-value specialty product with substantial revenue exposure.
Weaknesses
- Small-molecule patents face standard validity challenges.
- Later-issued formulation and method patents may provide narrower protection.
- Fourth-line treatment creates a relatively limited market.
- Generic companies can pursue non-infringing formulations or label carve-outs.
- Patent litigation can begin before the product reaches peak maturity.
The estate is stronger than the regulatory exclusivity profile alone would suggest, but it is not immune to Paragraph IV litigation or an at-risk generic launch.
How does ripretinib compare with competing GIST drugs?
| Drug |
Brand |
Company |
Primary GIST position |
Competitive effect |
| Imatinib |
Gleevec and generics |
Novartis, generic manufacturers |
First line |
Creates the treatment base but has low current pricing |
| Sunitinib |
Sutent and generics |
Pfizer, generic manufacturers |
Second line |
Generic competition limits commercial value |
| Regorafenib |
Stivarga |
Bayer |
Third line |
Direct predecessor to Qinlock |
| Ripretinib |
Qinlock |
Ono Pharmaceutical |
Fourth line |
Strongest position after multiple kinase inhibitors |
| Avapritinib |
Ayvakit |
Blueprint Medicines |
PDGFRA exon 18 and earlier-line GIST uses |
Expands competition in molecularly defined and earlier-line patients |
Avapritinib is the most important branded competitive threat. Its activity in PDGFRA exon 18-mutant GIST gives it a differentiated molecular niche, while its expansion into earlier-line disease increases overlap with the broader GIST treatment market.[8]
Qinlock remains differentiated in later-line GIST because its clinical development and FDA approval directly address patients who have progressed through three prior kinase inhibitors. The competitive risk increases if earlier-line therapies improve survival and reduce the number of patients reaching fourth-line treatment.
What biosimilar risk exists for ripretinib?
Biosimilar risk is not applicable to ripretinib because Qinlock is a chemically synthesized small-molecule drug, not a biologic. The relevant threat is an ANDA-based generic, not a biosimilar filed under the Biologics Price Competition and Innovation Act.
Generic risk is likely to emerge through:
- Paragraph IV patent certifications.
- Paragraph III certifications after patent expiry.
- Section viii label carve-outs.
- Challenges to formulation patents.
- Patent settlements allowing delayed entry.
Because Qinlock is an oral tablet, generic development is technically less complex than development of a biologic. The main barriers are patent rights, regulatory bioequivalence and commercial scale.
What licensing deals cover ripretinib?
Deciphera retained the central commercial asset before Ono’s acquisition, while regional commercialization arrangements supported international expansion. Deciphera entered into an agreement with Zai Lab for development and commercialization of Qinlock in Greater China.[9]
The Ono acquisition transferred Deciphera’s rights and obligations to Ono. Ono therefore controls the global strategic direction of Qinlock, subject to existing regional agreements, regulatory rights and local commercialization arrangements.
The transaction is more important than a conventional licensing deal because Ono obtained the entire Deciphera portfolio, commercial infrastructure and development organization rather than only a territorial license.
What is the FDA regulatory status of ripretinib?
Qinlock has full FDA approval for advanced GIST after treatment with at least three prior kinase inhibitors, including imatinib.[1]
Key regulatory milestones include:
| Date |
Milestone |
| May 2020 |
FDA approval for advanced GIST after three or more prior kinase inhibitors |
| 2020 |
U.S. commercial launch |
| 2021 onward |
Expansion of international regulatory and commercial availability |
| May 2025 |
End of five-year NCE exclusivity |
| May 2027 |
Approximate end of U.S. orphan exclusivity for the approved indication |
There is no FDA-approved ripretinib indication for earlier-line GIST that would materially enlarge the label beyond the current advanced-disease setting.
What generic launch scenarios exist for Qinlock?
Three launch scenarios are commercially relevant.
Delayed generic entry
Ono successfully defends the core patents, and generics enter only after final patent expiry in the mid-2030s. This outcome preserves the longest period of branded revenue.
Settled entry
Ono reaches a settlement with one or more ANDA applicants. The settlement could permit entry before the nominal patent expiry date while preserving several years of branded sales. Terms may include a licensed launch date, restrictions on authorized generic supply and resolution of patent claims.
Early or at-risk entry
A generic challenger invalidates or avoids key patents, or launches while litigation continues. This would cause rapid price erosion, particularly if multiple manufacturers enter simultaneously. A fourth-line oncology product could experience meaningful revenue loss even if branded demand remains stable because payers generally favor lower-cost generic alternatives.
What is the revenue exposure to Ono?
Qinlock is a strategic commercial asset but not a company-defining product on the scale of a first-line oncology blockbuster. Before acquisition, annual revenue exceeded $200 million and continued to grow. The product contributes recurring cash flow, supports Ono’s oncology portfolio and provides a platform for further GIST commercialization.
The main financial risks are:
- Slower growth as U.S. fourth-line penetration matures.
- Earlier-line competition from avapritinib.
- Smaller-than-expected international markets.
- Generic entry after regulatory exclusivity.
- Failure to secure new indications.
- Reimbursement pressure in Europe and other price-regulated markets.
The principal upside is treatment-duration expansion, greater international uptake and successful development in earlier lines or molecularly selected GIST.
Key Takeaways
- Ripretinib, marketed as Qinlock, is FDA approved for advanced GIST after three or more prior kinase inhibitors.
- Qinlock revenue grew from approximately $43 million in 2020 to approximately $211 million in 2023.
- Ono acquired Deciphera in 2024 for approximately $2.4 billion and now controls Qinlock.
- U.S. new chemical entity exclusivity expired in May 2025, while orphan exclusivity generally extends through May 2027.
- Core patent protection is expected to extend into the mid-2030s, subject to final patent-term calculations.
- Generic, rather than biosimilar, competition is the relevant long-term threat.
- Avapritinib is the most important branded competitor because of its molecular differentiation and earlier-line GIST positioning.
- Qinlock’s revenue ceiling is constrained by its fourth-line label, but its patent estate and recurring specialty-oncology demand support a durable commercial franchise.
- The highest-value development opportunity is expansion into earlier treatment lines or additional molecularly defined GIST populations.
FAQs about ripretinib exclusivity, competition, and investment risk
Is Qinlock still protected after FDA exclusivity expires?
Yes. FDA regulatory exclusivity and patent protection are separate. Qinlock’s five-year new chemical entity exclusivity ended in 2025, but U.S. patents are expected to protect the product into the 2030s.
Is ripretinib a biologic or a small-molecule drug?
Ripretinib is a small-molecule kinase inhibitor. Generic applicants would use the ANDA pathway rather than the biosimilar pathway.
What is the biggest commercial risk to Qinlock?
The main risk is limited market expansion because Qinlock is approved primarily for fourth-line GIST. Earlier-line competitors can reduce the number of patients who progress to the Qinlock treatment setting.
Does avapritinib replace ripretinib?
No. The drugs have overlapping GIST relevance but different clinical positions. Avapritinib has particular value in PDGFRA exon 18-mutant disease and earlier-line treatment, while ripretinib is established after multiple prior kinase inhibitors.
Why did Ono acquire Deciphera?
Ono acquired Deciphera to obtain Qinlock, vimseltinib, oncology development capabilities and a commercial U.S. specialty-pharmaceutical platform. Qinlock’s recurring revenue and patent life were central economic components of the transaction.
References
- U.S. Food and Drug Administration. (2020). Qinlock (ripretinib) prescribing information.
- Blay, J.-Y., Serrano, C., Heinrich, M. C., Zalcberg, J., Bauer, S., Gelderblom, H., et al. (2020). Ripretinib in patients with advanced gastrointestinal stromal tumours. The Lancet Oncology, 21(7), 923-934.
- Deciphera Pharmaceuticals, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.
- Deciphera Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
- Deciphera Pharmaceuticals, Inc. (2024). First-quarter 2024 financial results and business updates.
- Ono Pharmaceutical Co., Ltd. (2024). Ono to acquire Deciphera Pharmaceuticals.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Ayvakit (avapritinib) prescribing information.
- Zai Lab Limited. (2021). Zai Lab and Deciphera Pharmaceuticals announce China approval of Qinlock for advanced GIST.
